Eyes on New Product Development

Gary D. Novack

IN THE RECENT period, approvals were received for a number of retinal products throughout the world, a postoperative care product will be reviewed by a U.S. Food and Drug Administration (FDA) advisory panel, and a novel glaucoma implant has completed a 1-year study.

Ophthalmic Pharmaceuticals

- Alcon received approval for JETREA™ (ocriplasmin for intravitreal injection) in patients with symptomatic vitreomacular adhesion in Canada (August 2013).
- Alimera announced that Iluvien® (fluocinolone acetonide for intravitreal injection) has been listed for reimbursement in France (July 2013).
- InSite Vision completed dosing and analysis of a study of AzaSite Plus™ (azithromycin and dexamethasone) and DexaSite™ (dexamethasone) in patients with blepharitis (August 2013).
- Regeneron and Bayer's Eylea® (aflibercept) was allowed for reimbursement by the U.K.'s National Institute for Health and Care Excellence (May 2013). Two studies evaluating aflibercept solution (Eylea) for the treatment of diabetic macular edema have been completed and analyzed (August 2013).

Other Ophthalmic Products

- Ivantis completed 1-year dosing and analysis of a 1-year study of its Hydrus™ microstent device in patients with glaucoma (July 2013).
- Ocular Therapeutix announced that ReSure®, a hydrogel under review for postoperative care, will be discussed at an FDA advisory panel (August 2013).

Author Disclosure Statement

The author consults for numerous ophthalmic pharmaceutical and medical device firms.

Received: August 19, 2013

Accepted: August 20, 2013

Address correspondence to:
Dr. Gary D. Novack
PharmaLogic Development, Inc.
17 Bridgegate Drive
San Rafael, CA 94903

E-mail: gary_novack@pharmalogic.com